Skip to main content
Top
Published in: Current Treatment Options in Oncology 1/2012

01-03-2012 | Head and Neck Cancer (T Day, Section Editor)

Recurrent Salivary Gland Cancer

Authors: M. Boyd Gillespie, MD, MSc, W. Greer Albergotti, BS, David W. Eisele, MD

Published in: Current Treatment Options in Oncology | Issue 1/2012

Login to get access

Opinion statement

Salivary gland cancer is the most diverse cancer in the body consisting of up to 24 different pathologic subtypes. Although these cancers arise within a common group of glands in the head and neck region, these diverse cancers differ substantially in clinical behavior. As a result, salivary cancers are often categorized as low, intermediate, or high-risk for recurrence and metastasis based on histopathologic subtype and tumor stage. Appropriate risk classification of a given salivary tumor provides a useful guide to the physicians who determine the appropriate treatment regimen. Low-risk tumors can be treated successfully with surgery alone, whereas intermediate and high-risk tumors often require multimodality therapy. Recurrent salivary cancer should be considered high-risk by definition, especially if previously treated with appropriate therapy, and therefore requires aggressive multimodality therapy in order to achieve adequate local control and disease-free survival.
Literature
1.••
go back to reference Jeannon JP, Calman F, Gleeson M, et al. Management of advanced parotid cancer: a systematic review. Eur J Surg Oncol. 2009; 35: 908–915.PubMedCrossRef Jeannon JP, Calman F, Gleeson M, et al. Management of advanced parotid cancer: a systematic review. Eur J Surg Oncol. 2009; 35: 908–915.PubMedCrossRef
2.••
go back to reference Surakanti SG, Agulnik M. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol. 2008; 35: 309–319.PubMedCrossRef Surakanti SG, Agulnik M. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol. 2008; 35: 309–319.PubMedCrossRef
3.
go back to reference Lee YYP, Wong KT, King AD, Ahuja AT. Imaging of salivary gland tumors. Eur J Radiol. 2008;66:419–36.PubMedCrossRef Lee YYP, Wong KT, King AD, Ahuja AT. Imaging of salivary gland tumors. Eur J Radiol. 2008;66:419–36.PubMedCrossRef
4.
5.
go back to reference Keyes JW, Harkness BA, Greven KM, et al. Salivary gland tumors: pretherapy evaluation with PET. Radiology. 1994;192:99–102.PubMed Keyes JW, Harkness BA, Greven KM, et al. Salivary gland tumors: pretherapy evaluation with PET. Radiology. 1994;192:99–102.PubMed
7.•
go back to reference Cohen EG, Patel SG, Lin O, et al. Fine-needle aspiration biopsy of salivary gland lesions in a selected patient population. Arch Otolaryngol Head Neck Surg. 2004; 130: 773–778.PubMedCrossRef Cohen EG, Patel SG, Lin O, et al. Fine-needle aspiration biopsy of salivary gland lesions in a selected patient population. Arch Otolaryngol Head Neck Surg. 2004; 130: 773–778.PubMedCrossRef
8.
go back to reference Kaszuba SM, Zafereo ME, Rosenthal DI, et al. Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:546–50.PubMedCrossRef Kaszuba SM, Zafereo ME, Rosenthal DI, et al. Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:546–50.PubMedCrossRef
10.
go back to reference Skalova A, Leivo I, Von Boguslawsky K, Saksela E. Cell proliferation correlates with prognosis in acinic cell carcinomas of salivary gland origin. Immunohistochemical study of 30 cases using the MIB 1 antibody in formalin-fixed paraffin sections. J Pathol. 1994;173:13–21.PubMedCrossRef Skalova A, Leivo I, Von Boguslawsky K, Saksela E. Cell proliferation correlates with prognosis in acinic cell carcinomas of salivary gland origin. Immunohistochemical study of 30 cases using the MIB 1 antibody in formalin-fixed paraffin sections. J Pathol. 1994;173:13–21.PubMedCrossRef
11.
go back to reference Luukkaa H, Klemi P, Leivo I, et al. Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases. Acta Oncol. 2006;45:669–75.PubMedCrossRef Luukkaa H, Klemi P, Leivo I, et al. Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases. Acta Oncol. 2006;45:669–75.PubMedCrossRef
12.
go back to reference Nordgard S, Franzen G, Boysen M, Halvorsen TB. Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. Laryngoscope. 1997;107:531–6.PubMedCrossRef Nordgard S, Franzen G, Boysen M, Halvorsen TB. Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. Laryngoscope. 1997;107:531–6.PubMedCrossRef
13.
go back to reference Miyabe S, Okabe M, Nagatsuka H, et al. Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases. J Oral Maxillofac Surg. 2009;67(7):1432–41.PubMedCrossRef Miyabe S, Okabe M, Nagatsuka H, et al. Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases. J Oral Maxillofac Surg. 2009;67(7):1432–41.PubMedCrossRef
14.
go back to reference Hoyek-Gebeily J, Nehme E, Aftimos G, et al. Prognostic significance of EGFR, p53 and E-cadherin in mucoepidermoid cancer of the salivary glands: a retrospective case series. J Med Liban. 2007;55:83–8.PubMed Hoyek-Gebeily J, Nehme E, Aftimos G, et al. Prognostic significance of EGFR, p53 and E-cadherin in mucoepidermoid cancer of the salivary glands: a retrospective case series. J Med Liban. 2007;55:83–8.PubMed
15.
go back to reference Karja VJ, Syrjanen KJ, Kurvinen AK, Syrjanen SM. Expression and mutations of p53 in salivary gland tumours. J Oral Path Med. 1997;26:217–23.CrossRef Karja VJ, Syrjanen KJ, Kurvinen AK, Syrjanen SM. Expression and mutations of p53 in salivary gland tumours. J Oral Path Med. 1997;26:217–23.CrossRef
16.
go back to reference Kiyoshima T, Shima K, Kobayashi I, et al. Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands. Oral Oncol. 2001;37:315–7.PubMedCrossRef Kiyoshima T, Shima K, Kobayashi I, et al. Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands. Oral Oncol. 2001;37:315–7.PubMedCrossRef
17.•
go back to reference Williams MD, Roberts DB, Lies MS, et al. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Can Res. 2010; 16: 2266–2274.CrossRef Williams MD, Roberts DB, Lies MS, et al. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Can Res. 2010; 16: 2266–2274.CrossRef
18.
go back to reference Seethala RR, Dacic S, Cieply K, et al. A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol. 2010;34:1106–21.PubMedCrossRef Seethala RR, Dacic S, Cieply K, et al. A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol. 2010;34:1106–21.PubMedCrossRef
19.
go back to reference Okabe M, Miyabe S, Nagatsuka H, et al. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Can Res. 2006;12:3902–7.CrossRef Okabe M, Miyabe S, Nagatsuka H, et al. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Can Res. 2006;12:3902–7.CrossRef
20.
go back to reference Okumura Y, Miyabe S, Nakayama T, et al. Impact of CRTC1/3-MAML2 fusions on histological classification and prognosis of mucoepidermoid carcinoma. Histopathology. 2011;59:90–7.PubMedCrossRef Okumura Y, Miyabe S, Nakayama T, et al. Impact of CRTC1/3-MAML2 fusions on histological classification and prognosis of mucoepidermoid carcinoma. Histopathology. 2011;59:90–7.PubMedCrossRef
21.
go back to reference Ben-Izhak O, Akrish S, Gan S, Nagler RM. p27 and salivary cancer. Cancer Immunol Immunother. 2009;58:469–73.PubMedCrossRef Ben-Izhak O, Akrish S, Gan S, Nagler RM. p27 and salivary cancer. Cancer Immunol Immunother. 2009;58:469–73.PubMedCrossRef
22.••
go back to reference Terhaard CHJ. Postoperative and primary radiotherapy for salivary gland carcinomas: indications, techniques, and results. Int J Radiat Oncol Biol Phys. 2007; 69 Suppl: S52–S55. Excellent review of the role of radiotherapy for salivary cancer summarizing evidence concerning major issues. Terhaard CHJ. Postoperative and primary radiotherapy for salivary gland carcinomas: indications, techniques, and results. Int J Radiat Oncol Biol Phys. 2007; 69 Suppl: S52–S55. Excellent review of the role of radiotherapy for salivary cancer summarizing evidence concerning major issues.
23.
go back to reference Alterio D, Jereczek-Fossa BA, Griseri M, et al. Three-dimensional conformal postoperative radiotherapy in patients with parotid tumors: 10 years experience at the European Institute of Oncology. Tumori. 2011;97:328–34.PubMed Alterio D, Jereczek-Fossa BA, Griseri M, et al. Three-dimensional conformal postoperative radiotherapy in patients with parotid tumors: 10 years experience at the European Institute of Oncology. Tumori. 2011;97:328–34.PubMed
24.••
go back to reference Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol. 2009; 45: 574–578.PubMedCrossRef Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol. 2009; 45: 574–578.PubMedCrossRef
25.
go back to reference Mariano FV, da Silva SD, Chulan TC, et al. Clinicopathological factors are predictors of distant metastasis from major salivary gland carcinomas. Int J Oral Maxillofac Surg. 2011;40:504–9.PubMedCrossRef Mariano FV, da Silva SD, Chulan TC, et al. Clinicopathological factors are predictors of distant metastasis from major salivary gland carcinomas. Int J Oral Maxillofac Surg. 2011;40:504–9.PubMedCrossRef
26.•
go back to reference Westra WH, Kronz JD, Eisele DW. The impact of second opinion surgical pathology on the practice of head and neck surgery: a decade experience at a large referral hospital. Head Neck 2002; 24: 684–693.PubMedCrossRef Westra WH, Kronz JD, Eisele DW. The impact of second opinion surgical pathology on the practice of head and neck surgery: a decade experience at a large referral hospital. Head Neck 2002; 24: 684–693.PubMedCrossRef
27.
go back to reference Kobayashi K, Nakao K, Yoshida M, et al. Recurrent cancer of the parotid gland: how well does surgery work for locoregional failure? ORL J Otorhinolaryngol Relat Spec. 2009;71:239–43.PubMedCrossRef Kobayashi K, Nakao K, Yoshida M, et al. Recurrent cancer of the parotid gland: how well does surgery work for locoregional failure? ORL J Otorhinolaryngol Relat Spec. 2009;71:239–43.PubMedCrossRef
28.•
go back to reference Pederson AW, Haraf DJ, Blair EA, et al. Chemoreirradiation for recurrent salivary malignancies. Radiother Oncol. 2010; 95: 308–311. Paper provides evidence of the relative safety of reirradiation protocols in recurrent salivary cancer.PubMedCrossRef Pederson AW, Haraf DJ, Blair EA, et al. Chemoreirradiation for recurrent salivary malignancies. Radiother Oncol. 2010; 95: 308–311. Paper provides evidence of the relative safety of reirradiation protocols in recurrent salivary cancer.PubMedCrossRef
29.••
go back to reference Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011; 12: 815–824.PubMedCrossRef Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011; 12: 815–824.PubMedCrossRef
30.
go back to reference Papaspyrou G, Hoch S, Rinaldo A, et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011; 905–911. Papaspyrou G, Hoch S, Rinaldo A, et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011; 905–911.
31.
go back to reference Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer. Cancer. 2010;116:362–8.PubMedCrossRef Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer. Cancer. 2010;116:362–8.PubMedCrossRef
32.
go back to reference Debaere D, Vander Poorten V, Nuyts S, et al. Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. B-ENT. 2011;7:1–6.PubMed Debaere D, Vander Poorten V, Nuyts S, et al. Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. B-ENT. 2011;7:1–6.PubMed
33.
go back to reference Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas: a phase 2 study. Oral Oncol. 2003;39:724–7.PubMedCrossRef Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas: a phase 2 study. Oral Oncol. 2003;39:724–7.PubMedCrossRef
Metadata
Title
Recurrent Salivary Gland Cancer
Authors
M. Boyd Gillespie, MD, MSc
W. Greer Albergotti, BS
David W. Eisele, MD
Publication date
01-03-2012
Publisher
Current Science Inc.
Published in
Current Treatment Options in Oncology / Issue 1/2012
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-011-0174-0

Other articles of this Issue 1/2012

Current Treatment Options in Oncology 1/2012 Go to the issue

Head and Neck Cancer (T Day, Section Editor)

Current Treatment Options for Metastatic Head and Neck Cancer

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Parathyroid Carcinoma: Update and Guidelines for Management

Head and Neck Cancer (T Day, Section Editor)

Well Differentiated Thyroid Carcinoma: Current Treatment

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine